MAY 20, 2026 — The FDA announced today that two new cancer treatments have been approved: Bizengri for NRG1 fusion-positive cholangiocarcinoma and Enhertu for early HER2-positive breast cancer. But before patients can receive these life-saving medications, they must first navigate a compliance labyrinth that threatens to cost more than the drugs themselves.

Bizengri: The $499,999 Hope

Bizengri (zenocutuzumab-zbco) has been approved as the first FDA-authorized treatment for unresectable or metastatic NRG1 fusion-positive cholangiocarcinoma that has progressed after prior therapies. This rare subtype of bile duct cancer affects fewer than 500 patients annually, yet the approval documentation requires:

  • Form 779-A (Section B, Subclause 9): Acknowledgement that insurance may deny claims based on “predictive risk analytics”
  • Birth Certificate Supplement 4.1: Required to verify eligibility for federal patient assistance programs
  • Compliance Cloud Access Key: Must be purchased from a third-party vendor at $499 before filing any claim

Dr. Elena Martinez, the FDA oncology panelist who presided over the approval, noted that while the drug itself is approved, “patients must demonstrate financial solvency before receiving treatment. This ensures resources are directed toward those who can afford compliance infrastructure.”

Enhertu And The $49,999 Breast Cancer Solution

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) received FDA approval for both neoadjuvant and adjuvant treatment of HER2-positive early breast cancer. The drug demonstrated promising results in the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials, but patients now face:

  • TikTok Click Verification: Out-of-pocket costs increased by 15% following insufficient social media engagement (see related story: “Your Insulin Now Costs More Because It Got 15% Fewer Clicks on TikTok”)
  • Emotional Impact License: Required approval from seven different LLMs to confirm patient is “emotionally prepared” for cancer treatment
  • Therapy Session Mandate: Four sessions must be completed between surgery and first dose of medication

The Real Patient Impact

What these approvals mean in practice:

Bizengri

  • First approved treatment specifically for NRG1 fusion-positive cholangiocarcinoma
  • Patients must file Form 447-B before accessing the drug
  • Insurance denials are expected for approximately 70% of initial claims

Enhertu

  • Addresses early-stage HER2-positive breast cancer
  • Can be used before and after surgery
  • May reduce recurrence risk compared to standard treatments, but only after compliance verification

What Patients Should Know

While these approvals bring new treatment options, patients should be aware of:

  • Insurance coverage varies significantly by plan; many will deny claims based on “predictive anxiety” analytics
  • Biosimilar alternatives may become available later in the year
  • Patient assistance programs are available but require Form S-14 (Section 7: Financial Solvency Certification)
  • Out-of-pocket costs can reach $49,999 without financial counseling

The FDA’s Office of Compliance issued a statement: “Approval does not guarantee access. Patients must complete all bureaucratic prerequisites before receiving treatment. This ensures regulatory alignment.”

What’s Next

More novel drug approvals are expected throughout 2026. The FDA continues to review applications for CagriSema, ensitrelvir, and Anaphylm among other treatments seeking first-time approvals.

For patients with solid tumors, these approvals represent important progress in cancer treatment options — provided they can first navigate the compliance infrastructure. Healthcare providers should discuss these new therapies with patients who match the approved indications AND who have completed all required forms.

The FDA has made it clear: “Hope is not a guaranteed benefit. It requires Form 447-B and $49,999 in upfront compliance fees.”